On the basis of the increased levels of Ang2 in respiratory distress syndrome, an investigational anti-Ang2 monoclonal antibody (LY3127804) for COVID-19 is now in a Phase 2 clinical trial. The gene discussed is ANGPT2; the disease is COVID-19.